ABSTRACT
Exposure to toxic metals impacts obesity and type 2 diabetes (T2DM) risk. Yet, the underlying mechanisms remain largely unknown. Gut microbiota has been strongly associated with progression of cardiometabolic risk. To determine whether high metal exposures and gut dysbiosis interact to promote metabolic dysregulation and cardiometabolic risk, we assessed relationships between these factors. We analyzed cross-sectional associations between arsenic, lead, mercury, cadmium, and cardiometabolic health markers in 178 randomly selected African-origin adults (52% female, 51% obese, mean age=43.0±6.4 years) from Ghana, South Africa, Seychelles, Jamaica, and USA. Metal levels were dichotomized to high or low at the median level of each metal. We analyzed associations between gut microbiome taxa, metal levels, clinical measures (BMI, fasting blood glucose, and blood pressure) and diagnoses (hypertension, obesity, and diabetes status). High vs. low lead and arsenic exposures had a significant effect on beta diversity (p <0.05). 71 taxa were associated with high lead levels: 30 with elevated BMI, 22 with T2DM, and 23 with elevated fasting blood glucose (p<0.05). 115 taxa were associated with high arsenic levels: 32 with elevated BMI, 33 with T2DM, and 26 with elevated blood glucose (p<0.05). Of the taxa associated with high lead and arsenic exposure and either elevated BMI or fasting blood glucose, porphyrin metabolism was the most enriched metabolic pathway. These data collectively provide the first findings in a human study that the gut microbiome may drive the association between lead and arsenic exposure and obesity and T2DM risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health (R01 DK070853 and R01 DK111848 supporting AL and LRD; P30 ES027792 supporting RMS and MA; R01 ES028879 and R21 ES030884 supporting RMS; R01 DK104927 supporting BTL), the United States Department of Veterans Affairs (I01 BX00382 supporting BTL and I01 BX006108 supporting RMS), and the United States Department of Defense (TX220140 supporting RMS). Sequence data generated at the UC San Diego IGM Genomics Center with an Illumina NovaSeq 6000 was purchased with funding from a National Institutes of Health SIG grant under Award Number S10 OD026929 (J.A.G.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Loyola University Chicago, IL, US gave ethical approval for this work: METS (IRB: LU200038) and METS-Microbiome (IRB: LU209537). This was the central coordinating center for both projects. The Committee on Human Research Publication and Ethics of Kwame Nkrumah University of Science and Technology, Kumasi, Ghana gave ethical approval for this work. The Research Ethics Committee of the University of Cape Town, South Africa gave ethical approval for this work. The Board for Ethics and Clinical Research of the University of Lausanne, Switzerland gave ethical approval for this work. The Health Research and Ethics Committee of the Ministry of Health of Seychelles gave ethical approval for this work. The Ethics Committee of the University of the West Indies, Kingston, Jamaica gave ethical approval for this work. All study procedures were explained to participants in their native languages, and participants were provided written informed consent after being given the opportunity to ask any questions and compensated for their participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The clinical and metadata are available under restricted access due to privacy regulations of our cohort. All data produced in the present study are available upon reasonable request to the authors. The SILVA 16 S rRNA database used for alignment is available at https://data.qiime2.org/2022.2/common/silva-138-99-515-806-nb-classifier.qza and the MetaCyc Databases are available at https://metacyc.org/.